208 related articles for article (PubMed ID: 37170266)
1. Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody.
Faresjö R; Sehlin D; Syvänen S
Fluids Barriers CNS; 2023 May; 20(1):34. PubMed ID: 37170266
[TBL] [Abstract][Full Text] [Related]
2. Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size.
Faresjö R; Bonvicini G; Fang XT; Aguilar X; Sehlin D; Syvänen S
Fluids Barriers CNS; 2021 Jun; 18(1):26. PubMed ID: 34078410
[TBL] [Abstract][Full Text] [Related]
3. Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer's disease mice measured by high cut-off microdialysis.
Julku U; Xiong M; Wik E; Roshanbin S; Sehlin D; Syvänen S
Fluids Barriers CNS; 2022 Dec; 19(1):99. PubMed ID: 36510227
[TBL] [Abstract][Full Text] [Related]
4. Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies.
Faresjö R; Lindberg H; Ståhl S; Löfblom J; Syvänen S; Sehlin D
Pharm Res; 2022 Jul; 39(7):1509-1521. PubMed ID: 35538266
[TBL] [Abstract][Full Text] [Related]
5. Indium-111 radiolabelling of a brain-penetrant Aβ antibody for SPECT imaging.
Gustavsson T; Herth MM; Sehlin D; Syvänen S
Ups J Med Sci; 2024; 129():. PubMed ID: 38863725
[TBL] [Abstract][Full Text] [Related]
6. SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer's disease.
Gustavsson T; Syvänen S; O'Callaghan P; Sehlin D
Transl Neurodegener; 2020 Sep; 9(1):37. PubMed ID: 32951598
[TBL] [Abstract][Full Text] [Related]
7. A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer's Disease Mice.
Rofo F; Meier SR; Metzendorf NG; Morrison JI; Petrovic A; Syvänen S; Sehlin D; Hultqvist G
Neurotherapeutics; 2022 Sep; 19(5):1588-1602. PubMed ID: 35939261
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of immunotherapy with a brain penetrating Aβ antibody in a mouse model of Alzheimer's disease.
Gustavsson T; Metzendorf NG; Wik E; Roshanbin S; Julku U; Chourlia A; Nilsson P; Andersson KG; Laudon H; Hultqvist G; Syvänen S; Sehlin D
Alzheimers Res Ther; 2023 May; 15(1):90. PubMed ID: 37131196
[TBL] [Abstract][Full Text] [Related]
9. Passive and receptor mediated brain delivery of an anti-GFAP nanobody.
Meier SR; Sehlin D; Syvänen S
Nucl Med Biol; 2022; 114-115():121-127. PubMed ID: 35487832
[TBL] [Abstract][Full Text] [Related]
10. Blood-brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer's disease.
Rofo F; Metzendorf NG; Saubi C; Suominen L; Godec A; Sehlin D; Syvänen S; Hultqvist G
Alzheimers Res Ther; 2022 Dec; 14(1):180. PubMed ID: 36471433
[TBL] [Abstract][Full Text] [Related]
11. Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody.
Syvänen S; Hultqvist G; Gustavsson T; Gumucio A; Laudon H; Söderberg L; Ingelsson M; Lannfelt L; Sehlin D
Alzheimers Res Ther; 2018 May; 10(1):49. PubMed ID: 29793530
[TBL] [Abstract][Full Text] [Related]
12. Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody.
Schlein E; Andersson KG; Dallas T; Syvänen S; Sehlin D
MAbs; 2024; 16(1):2339337. PubMed ID: 38634473
[TBL] [Abstract][Full Text] [Related]
13. High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain.
Fang XT; Hultqvist G; Meier SR; Antoni G; Sehlin D; Syvänen S
Neuroimage; 2019 Jan; 184():881-888. PubMed ID: 30300753
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition.
Meier SR; Syvänen S; Hultqvist G; Fang XT; Roshanbin S; Lannfelt L; Neumann U; Sehlin D
J Nucl Med; 2018 Dec; 59(12):1885-1891. PubMed ID: 29853653
[TBL] [Abstract][Full Text] [Related]
15. A single-chain fragment constant design enables easy production of a monovalent blood-brain barrier transporter and provides an improved brain uptake at elevated doses.
Morrison JI; Metzendorf NG; Rofo F; Petrovic A; Hultqvist G
J Neurochem; 2023 May; 165(3):413-425. PubMed ID: 36681883
[TBL] [Abstract][Full Text] [Related]
16. A bispecific Tribody PET radioligand for visualization of amyloid-beta protofibrils - a new concept for neuroimaging.
Syvänen S; Fang XT; Hultqvist G; Meier SR; Lannfelt L; Sehlin D
Neuroimage; 2017 Mar; 148():55-63. PubMed ID: 28069541
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.
Yu YJ; Atwal JK; Zhang Y; Tong RK; Wildsmith KR; Tan C; Bien-Ly N; Hersom M; Maloney JA; Meilandt WJ; Bumbaca D; Gadkar K; Hoyte K; Luk W; Lu Y; Ernst JA; Scearce-Levie K; Couch JA; Dennis MS; Watts RJ
Sci Transl Med; 2014 Nov; 6(261):261ra154. PubMed ID: 25378646
[TBL] [Abstract][Full Text] [Related]
18. ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer's disease with a bispecific, brain-penetrating fusion protein.
Bonvicini G; Syvänen S; Andersson KG; Haaparanta-Solin M; López-Picón F; Sehlin D
Transl Neurodegener; 2022 Dec; 11(1):55. PubMed ID: 36567338
[TBL] [Abstract][Full Text] [Related]
19. Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide.
Sumbria RK; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Mol Pharm; 2013 Sep; 10(9):3507-13. PubMed ID: 23924247
[TBL] [Abstract][Full Text] [Related]
20. Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain.
Gadkar K; Yadav DB; Zuchero JY; Couch JA; Kanodia J; Kenrick MK; Atwal JK; Dennis MS; Prabhu S; Watts RJ; Joseph SB; Ramanujan S
Eur J Pharm Biopharm; 2016 Apr; 101():53-61. PubMed ID: 26820920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
